Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancerCitation formats

Standard

Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer. / WANG, Y; Gavan, Sean; Steinke, Douglas; Cheung, Kwok-Leung; Chen, Li-Chia.

In: Cost Effectiveness and Resource Allocation, Vol. 20, 9, 01.03.2022.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{44695ebc186c4556bafefe40fb758c26,
title = "Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer",
abstract = "ObjectiveTo appraise the sources of evidence and methods to estimate input parameter values in decision-analytic model-based cost-effectiveness analyses of treatments for primary breast cancer (PBC) in older patients (≥ 70 years old).MethodsTwo electronic databases (Ovid Medline, Ovid EMBASE) were searched (inception until 5 September-2021) to identify model-based full economic evaluations of treatments for older women with PBC as part of their base-case target population or age-subgroup analysis. Data sources and methods to estimate four types of input parameters including health-related quality of life (HRQoL); natural history; treatment effect; resource use were extracted and appraised. Quality assessment was completed by reference to the Consolidated Health Economic Evaluation Reporting Standards.ResultsSeven model-based economic evaluations were included (older patients as part of their base-case (n = 3) or subgroup (n = 4) analysis). Data from younger patients (< 70 years) were used frequently to estimate input parameters. Different methods were adopted to adjust these estimates for an older population (HRQoL: disutility multipliers, additive utility decrements; Natural history: calibration of absolute values, one-way sensitivity analyses; Treatment effect: observational data analysis, age-specific behavioural parameters, plausible scenario analyses; Resource use: matched control observational data analysis, age-dependent follow-up costs).ConclusionImproving estimated input parameters for older PBC patients will improve estimates of cost-effectiveness, decision uncertainty, and the value of further research. The methods reported in this review can inform future cost-effectiveness analyses to overcome data challenges for this population. A better understanding of the value of treatments for these patients will improve population health outcomes, clinical decision-making, and resource allocation decisions.",
author = "Y WANG and Sean Gavan and Douglas Steinke and Kwok-Leung Cheung and Li-Chia Chen",
year = "2022",
month = mar,
day = "1",
doi = "https://doi.org/10.1186/s12962-022-00342-7",
language = "English",
volume = "20",
journal = "Cost Effectiveness and Resource Allocation",
issn = "1478-7547",
publisher = "BioMed Central Ltd",

}

RIS

TY - JOUR

T1 - Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer

AU - WANG, Y

AU - Gavan, Sean

AU - Steinke, Douglas

AU - Cheung, Kwok-Leung

AU - Chen, Li-Chia

PY - 2022/3/1

Y1 - 2022/3/1

N2 - ObjectiveTo appraise the sources of evidence and methods to estimate input parameter values in decision-analytic model-based cost-effectiveness analyses of treatments for primary breast cancer (PBC) in older patients (≥ 70 years old).MethodsTwo electronic databases (Ovid Medline, Ovid EMBASE) were searched (inception until 5 September-2021) to identify model-based full economic evaluations of treatments for older women with PBC as part of their base-case target population or age-subgroup analysis. Data sources and methods to estimate four types of input parameters including health-related quality of life (HRQoL); natural history; treatment effect; resource use were extracted and appraised. Quality assessment was completed by reference to the Consolidated Health Economic Evaluation Reporting Standards.ResultsSeven model-based economic evaluations were included (older patients as part of their base-case (n = 3) or subgroup (n = 4) analysis). Data from younger patients (< 70 years) were used frequently to estimate input parameters. Different methods were adopted to adjust these estimates for an older population (HRQoL: disutility multipliers, additive utility decrements; Natural history: calibration of absolute values, one-way sensitivity analyses; Treatment effect: observational data analysis, age-specific behavioural parameters, plausible scenario analyses; Resource use: matched control observational data analysis, age-dependent follow-up costs).ConclusionImproving estimated input parameters for older PBC patients will improve estimates of cost-effectiveness, decision uncertainty, and the value of further research. The methods reported in this review can inform future cost-effectiveness analyses to overcome data challenges for this population. A better understanding of the value of treatments for these patients will improve population health outcomes, clinical decision-making, and resource allocation decisions.

AB - ObjectiveTo appraise the sources of evidence and methods to estimate input parameter values in decision-analytic model-based cost-effectiveness analyses of treatments for primary breast cancer (PBC) in older patients (≥ 70 years old).MethodsTwo electronic databases (Ovid Medline, Ovid EMBASE) were searched (inception until 5 September-2021) to identify model-based full economic evaluations of treatments for older women with PBC as part of their base-case target population or age-subgroup analysis. Data sources and methods to estimate four types of input parameters including health-related quality of life (HRQoL); natural history; treatment effect; resource use were extracted and appraised. Quality assessment was completed by reference to the Consolidated Health Economic Evaluation Reporting Standards.ResultsSeven model-based economic evaluations were included (older patients as part of their base-case (n = 3) or subgroup (n = 4) analysis). Data from younger patients (< 70 years) were used frequently to estimate input parameters. Different methods were adopted to adjust these estimates for an older population (HRQoL: disutility multipliers, additive utility decrements; Natural history: calibration of absolute values, one-way sensitivity analyses; Treatment effect: observational data analysis, age-specific behavioural parameters, plausible scenario analyses; Resource use: matched control observational data analysis, age-dependent follow-up costs).ConclusionImproving estimated input parameters for older PBC patients will improve estimates of cost-effectiveness, decision uncertainty, and the value of further research. The methods reported in this review can inform future cost-effectiveness analyses to overcome data challenges for this population. A better understanding of the value of treatments for these patients will improve population health outcomes, clinical decision-making, and resource allocation decisions.

U2 - https://doi.org/10.1186/s12962-022-00342-7

DO - https://doi.org/10.1186/s12962-022-00342-7

M3 - Review article

VL - 20

JO - Cost Effectiveness and Resource Allocation

JF - Cost Effectiveness and Resource Allocation

SN - 1478-7547

M1 - 9

ER -